These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29109051)

  • 1. Evolving Concepts in the Management of Retinopathy of Prematurity.
    Sternberg P; Durrani AK
    Am J Ophthalmol; 2018 Feb; 186():xxiii-xxxii. PubMed ID: 29109051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
    Eldweik L; Mantagos IS
    Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).
    Tsai AS; Chou HD; Ling XC; Al-Khaled T; Valikodath N; Cole E; Yap VL; Chiang MF; Chan RVP; Wu WC
    Prog Retin Eye Res; 2022 May; 88():101018. PubMed ID: 34763060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
    Patel JR; Ranjan SS; Wasserman BN
    Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy.
    Tran KD; Cernichiaro-Espinosa LA; Berrocal AM
    Asia Pac J Ophthalmol (Phila); 2018; 7(1):56-62. PubMed ID: 29376233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity.
    Enríquez AB; Avery RL; Baumal CR
    Asia Pac J Ophthalmol (Phila); 2020; 9(4):358-368. PubMed ID: 32694348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights in diagnosis and treatment for Retinopathy of Prematurity.
    Cernichiaro-Espinosa LA; Olguin-Manriquez FJ; Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
    Int Ophthalmol; 2016 Oct; 36(5):751-60. PubMed ID: 26767656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
    VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
    Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity.
    Darwish D; Chee RI; Patel SN; Jonas K; Ostmo S; Campbell JP; Chiang MF; Chan RVP
    Asia Pac J Ophthalmol (Phila); 2018; 7(3):136-144. PubMed ID: 29808629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future trends in treatment of severe retinopathy of prematurity.
    Wallace DK; Wu KY
    Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot Topics in Retinopathy of Prematurity.
    Tsui I; Chu A
    Pediatr Ann; 2017 Nov; 46(11):e415-e422. PubMed ID: 29131921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Solutions in Retinopathy of Prematurity.
    Moshfeghi DM
    Am J Ophthalmol; 2018 Sep; 193():xiv-xviii. PubMed ID: 29792838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
    Klufas MA; Chan RV
    J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THE CUTTING EDGE OF RETINOPATHY OF PREMATURITY CARE: Expanding the Boundaries of Diagnosis and Treatment.
    Yonekawa Y; Thomas BJ; Thanos A; Todorich B; Drenser KA; Trese MT; Capone A
    Retina; 2017 Dec; 37(12):2208-2225. PubMed ID: 28541957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective.
    Chan-Ling T; Gole GA; Quinn GE; Adamson SJ; Darlow BA
    Prog Retin Eye Res; 2018 Jan; 62():77-119. PubMed ID: 28958885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
    Mititelu M; Chaudhary KM; Lieberman RM
    J Pediatr Ophthalmol Strabismus; 2012; 49(6):332-40. PubMed ID: 22938516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?
    Stahl A; Hellstrom A; Smith LE
    Neonatology; 2014; 106(3):254-60. PubMed ID: 25300950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review.
    Kandasamy Y; Hartley L; Rudd D; Smith R
    Br J Ophthalmol; 2017 Jan; 101(1):21-24. PubMed ID: 27388246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.